Cannabis Watchlist: Regulatory Momentum Reignites the Sector (April 2026)

The PRISM Cannabis Index jumped 13.7% yesterday, a single-session move that outpaced every other sector we track. This was not rotation or short-term noise. It reflected a clear response to renewed regulatory momentum.

Reports indicate the Trump Administration and Department of Justice are advancing the long-awaited reclassification of marijuana from Schedule I to Schedule III. The shift has been in motion since late 2025, but developments this week sharpened expectations around both timing and direction.

If it lands, the impact is significant. A move to Schedule III would ease the 280E tax burden, improve access to banking relationships, and improve access to institutional capital. After years of false starts, the market is beginning to treat this development with more credibility.

The largest, most liquid names led the move, with volume concentrated across widely followed operators. Here are four of the names drawing the most attention.

Curaleaf Holdings (OTC: CURLF)

Curaleaf is one of the largest U.S. multi-state operators. With more than 150 dispensaries across 17 states, a broad cultivation and processing network, and established brands including Curaleaf, Select, and Grassroots, it operates at a scale few peers can match.

The company generated roughly $1.27 billion in revenue last year while holding margins steady and producing positive free cash flow, a notable result in a tough pricing environment. What sets it apart is the growing international business in Europe, which provides revenue outside the U.S. regulatory cycle. When federal reform expectations shift, Curaleaf often moves quickly. It is the closest thing the sector has to a bellwether.

Tilray Brands (NASDAQ: TLRY)

Tilray takes a different approach. It is one of the most globally diversified names in cannabis, with a strong medical business in Europe, particularly Germany and the UK, a leadership position in Canada, and a growing consumer beverages platform that includes craft beer and spirits.

While many U.S.-focused operators are still waiting on reform, Tilray is already generating meaningful revenue outside the U.S. That international footprint, combined with its beverage diversification, offers investors a broader and less binary way to participate in the industry’s next phase.

Canopy Growth (NASDAQ: CGC)

As one of the original Canadian cannabis operators, Canopy continues to carry strong brand recognition. Its core business includes established lines like Tweed, 7ACRES, and DOJA, with particular strength in higher-margin categories such as vapes and edibles. The Storz & Bickel vaporizer business adds a steady source of profitability.

The more strategic piece is Canopy USA, its structured position in U.S. assets including Acreage, Wana, and Jetty. It is not fully consolidated today, but it provides a pathway to participate more directly once federal policy evolves.

SNDL Inc. (NASDAQ: SNDL)

SNDL brings a different mix. It operates Canada’s largest private-sector network of liquor and cannabis retail stores under banners including Ace Liquor, Value Buds, and Spiritleaf. That retail engine provides consistent cash flow, while its own cultivation and branded products layer in growth.

What stands out is the balance sheet: positive free cash flow, a clean capital structure, and improving margins. In a sector with a long history of burning cash, SNDL is one of the more operationally disciplined names and appears positioned for a longer cycle.

PRISM Take

This is the first time in months cannabis has moved on a real macro catalyst rather than speculation or isolated company news.

The framework is straightforward.
Tax relief drives better margins.
Better margins drive stronger cash flow.
Stronger cash flow can improve access to capital.

With more than half the country already in recreational states and public support for reform holding firm, the backdrop is beginning to shift. Timing and execution still matter, and this sector has a long record of testing investor patience. But right now, cannabis is back on the radar, with attention once again tied to underlying fundamentals.